CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


Montelukast 10mgWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (1)


Name (Synonyms) Correlation
drug2964 pregnant women with laboratory-confirmed 2019-n-CoV Wiki 0.71

Correlated MeSH Terms (2)


Name (Synonyms) Correlation
D014777 Virus Diseases NIH 0.12
D018352 Coronavirus Infections NIH 0.04

Correlated HPO Terms (0)


Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials


1 Repurposing Montelukast for the Attenuation and Prophylaxis of Severe COVID-19 Symptoms: The COvid-19 Symptom MOntelukast (COSMO) Trial

Due to the rapidly developing nature and severity of the COVID-19 pandemic, clinical trials involving a repurposed drug approach are the best option for rapidly identifying an effective COVID-19 therapeutic. The investigators propose to evaluate the efficacy of Montelukast in attenuating cytokine storm syndrome and ARDS via a randomized, blinded, placebo-controlled clinical trial. Specifically, our primary objective is comparing the efficacy of low-dose Montelukast versus placebo in reducing the risk of acute care visits and hospital admissions among COVID-19 positive patients in the general population.

NCT04389411 COVID-19 Drug: Montelukast 10mg

Primary Outcomes

Description: acute care use that includes a composite outcome comprised of being hospitalized and/or having visited an emergency room during follow-up.

Measure: Emergency Room Visits and Hospitalizations

Time: 12 weeks

Secondary Outcomes

Description: The number of emergency room visits

Measure: Emergency room visit count

Time: 12 weeks

Description: The number of hospitalizations

Measure: Hospitalization admission count

Time: 12 weeks

Measure: Time to ER Visit

Time: 12 weeks

Measure: Time to hospitalization

Time: 12 weeks

Measure: All-cause mortality

Time: 12 weeks

Measure: Inpatient Length of stay

Time: 12 weeks

Measure: Time to ICU admission

Time: 12 weeks

Measure: Time to intubation

Time: 12 weeks

Description: Complications will be defined as a composite endpoint including pneumonia, ARDS sepsis/septic shock, cardiomyopathy or arrhythmia, acute kidney injury, and secondary bacterial infections.

Measure: Time to other serious COVID-19 complications

Time: 12 weeks


No related HPO nodes (Using clinical trials)